Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307 is registered in ClinicalTrials.gov with Electra Therapeutics Inc. as lead sponsor.

NCT NCT05416307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05416307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Lead sponsor
Electra Therapeutics Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 19, 2022
Completion date
March 31, 2030
Enrollment
156 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hemophagocytic lymphohistiocytosis (shlh)